undamentalytics Newsletter

Sangrix Inc. (SGRX) stock

Add holding +

NASDAQ: SGRX Nasdaq Diversified Financial Services

Sangrix Inc. is a US-listed company in the diversified financial services industry. Its financial year ends in June.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Value diary

Our note on each quarter Sangrix files

Where Sangrix stands after its latest Filing

Sangrix has little or no product revenue yet; it used $3m of cash in the twelve months. The diluted share count is down 99.6% on a year earlier, which lifts each remaining share.

Our model value for Sangrix is under review, so past values are not shown until it is resolved.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Sangrix Inc.'s trailing-twelve-month revenue fell 98.6% year on year, with a free-cash-flow margin of -5799.7%.

Current signal Gross margin expanding: TTM gross margin reached 100.0%, up 132.7pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Strengths

  • Shrinking share count. Diluted shares fell 99.6% in a year, so each share owns more of the business.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 98.6% over the last 12 months.
  • Growth slowing. The growth rate is 44.8 points lower than a quarter earlier.
  • Loss-making. Operating margin is -7574.9%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 7061.2 points on a year ago.
  • Burning cash. Free cash flow was -5799.7% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 156% and a beta of 1.0 against the S&P 500.

Price chart

  • 1 day+0.5%
  • 1 week+82.7%
  • 1 month-41.4%
  • This year-98.6%
  • 1 year-99.3%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$39,495
Operating margin
-7574.9%
Net margin
-16543.8%
EPS (TTM, diluted)
$-70.43

Growth

Revenue growth
−98.6%
Change in growth rate
−44.8 pts
Share count change
−99.6%

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

No recent updates are available for SGRX from the sources we follow. See filings →

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Sangrix Inc.: too few analysts cover it.

Positioning

Short interest
2.8%
of tradable shares
Days to cover
0.04
at average volume
Short interest, 1 month
+80%
to October 15, 2026
Held by institutions
0%
of shares
Held by insiders
0.0%
of shares
Employees
5
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Sangrix Inc.: yearly return, monthly win rate and worst fall against the S&P 500
Calendar year 202120222023202420252026 to date
Return
SGRX+44%−87%−21%−76%−82%−99%
Industry peers (median)−4%−80%−44%−44%−14%−33%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
SGRX33%17%33%17%25%9%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
SGRX−55%−90%−90%−91%−88%−99%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since August 15, 2019: 100% from September 3, 2019 to October 27, 2026. Getting back needed a 11785614% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.38 – $99.60
From 52-week high
−99.3%
vs 50-day average
−48.9%
vs 200-day average
−90.9%
Volatility (1 year)
156%
Beta vs S&P 500
0.98

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Revenue (TTM) Sangrix Inc.
$0 $50M $100M $150M FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Revenue (TTM), FY17 Q4: $63.3M Revenue (TTM), FY18 Q4: $101.1M Revenue (TTM), FY19 Q4: $99.1M Revenue (TTM), FY20 Q4: $24.2M Revenue (TTM), FY21 Q4: $80.5M Revenue (TTM), FY22 Q4: $6.3M Revenue (TTM), FY23 Q4: $6.3M Revenue (TTM), FY24 Q4: $2.9M Revenue (TTM), FY25 Q4: $39.5K $39.5K

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY17 Q4 $63.3M
FY18 Q4 $101.1M
FY19 Q4 $99.1M
FY20 Q4 $24.2M
FY21 Q4 $80.5M
FY22 Q4 $6.3M
FY23 Q4 $6.3M
FY24 Q4 $2.9M
FY25 Q4 $39.5K
Revenue growth, TTM YoY Sangrix Inc.
-100% 0% 100% 200% 300% FY18 Q4 FY20 Q4 FY22 Q4 FY25 Q4 Revenue growth, TTM YoY, FY18 Q4: 59.8% Revenue growth, TTM YoY, FY19 Q4: -2.0% Revenue growth, TTM YoY, FY20 Q4: -75.5% Revenue growth, TTM YoY, FY21 Q4: 232.0% Revenue growth, TTM YoY, FY22 Q4: -92.2% Revenue growth, TTM YoY, FY23 Q4: 0.0% Revenue growth, TTM YoY, FY24 Q4: -53.9% Revenue growth, TTM YoY, FY25 Q4: -98.6% -98.6%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY18 Q4 59.8%
FY19 Q4 -2.0%
FY20 Q4 -75.5%
FY21 Q4 232.0%
FY22 Q4 -92.2%
FY23 Q4 0.0%
FY24 Q4 -53.9%
FY25 Q4 -98.6%
Operating margin (TTM) Sangrix Inc.
-8000% -6000% -4000% -2000% 0% 2000% FY17 Q4 FY19 Q4 FY21 Q4 FY23 Q4 FY25 Q4 Operating margin (TTM), FY17 Q4: 5.6% Operating margin (TTM), FY18 Q4: 7.0% Operating margin (TTM), FY19 Q4: -0.5% Operating margin (TTM), FY20 Q4: -14.2% Operating margin (TTM), FY21 Q4: -4.3% Operating margin (TTM), FY22 Q4: -452.1% Operating margin (TTM), FY23 Q4: -452.1% Operating margin (TTM), FY24 Q4: -513.6% Operating margin (TTM), FY25 Q4: -7574.9% -7574.9%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY17 Q4 5.6%
FY18 Q4 7.0%
FY19 Q4 -0.5%
FY20 Q4 -14.2%
FY21 Q4 -4.3%
FY22 Q4 -452.1%
FY23 Q4 -452.1%
FY24 Q4 -513.6%
FY25 Q4 -7574.9%
FCF margin (TTM) Sangrix Inc.
-6000% -4000% -2000% 0% FY17 Q4 FY19 Q4 FY22 Q4 FY25 Q4 FCF margin (TTM), FY17 Q4: -4.0% FCF margin (TTM), FY18 Q4: -3.6% FCF margin (TTM), FY19 Q4: -5.3% FCF margin (TTM), FY20 Q4: -27.3% FCF margin (TTM), FY22 Q4: -360.0% FCF margin (TTM), FY23 Q4: -109.8% FCF margin (TTM), FY24 Q4: -274.5% FCF margin (TTM), FY25 Q4: -5799.7% -5799.7%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY17 Q4 -4.0%
FY18 Q4 -3.6%
FY19 Q4 -5.3%
FY20 Q4 -27.3%
FY22 Q4 -360.0%
FY23 Q4 -109.8%
FY24 Q4 -274.5%
FY25 Q4 -5799.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 20-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Sangrix Inc.: annual financial statements
Fiscal year 2017 Jun 2017 2018 Jun 2018 2019 Jun 2019 2020 Jun 2020 2021 Jun 2021 2022 Jun 2022 2023 Jun 2023 2024 Jun 2024 2025 Jun 2025
Income
Revenue 63 101 99 24 80 6 6 3 0
Gross profit 5 10 9 2 3 −5 −5 −1 0
EBITDA 4 8 0 — — — −23 −14 −3
Operating income 4 7 −1 −3 −3 −28 −28 −15 −3
Net income 2 4 4 −5 −46 3 −28 −18 −7
Diluted EPS $648.00 $1026.00 $1134.00 — — −$1549.80 — −$1003.41 −$84.84
Growth (year on year)
Revenue — +59.8% −2.0% −75.5% +232.0% −92.2% 0.0% −53.9% −98.6%
EBITDA — +87.1% −97.6% — — — — — —
Operating income — +100.0% −107.3% — — — — — —
Net income — +53.5% +15.8% −211.8% — — −971.0% — —
Diluted EPS — +58.3% +10.5% — — — — — —
Margins
Gross margin 8.0% 9.5% 8.7% 8.4% 3.7% −72.9% −72.9% −32.7% 100.0%
EBITDA margin 6.4% 7.5% 0.2% — — — −366.4% −482.4% <−999%
Operating margin 5.6% 7.0% −0.5% −14.2% −4.3% −452.1% −452.1% −513.6% <−999%
Net margin 3.9% 3.7% 4.4% −20.1% −56.7% 51.7% −450.7% −607.0% <−999%
Free-cash-flow margin −4.0% −3.6% −5.3% −27.3% — −360.0% −109.8% −274.5% <−999%
Cash flow
Cash from operations −3 −4 −5 −6 −10 −14 −7 −8 −2
Capital spending 0 0 0 1 — 8 0 0 0
Free cash flow −3 −4 −5 −7 — −23 −7 −8 −2
Stock-based pay — 0 0 1 2 2 0 0 —
Free cash flow after stock pay — −4 −5 −8 — −24 −7 −8 —
Balance sheet
Cash 0 0 3 1 0 0 0 1 0
Total debt 0 5 6 8 10 — 2 — —
Net debt (negative = net cash) −0 5 4 7 10 −0 2 −1 −0
Diluted shares — — — — — 18m — — 77m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Dividends, buybacks and capital spending

Diluted share count
−99.6%
year over year

Competitors: side by side with peers

Closest by revenue in diversified financial services
Growth, margins and cash generation against peers
Last 12 months unless stated SGRX SNTG MI DCM GRAN RMCO Median
Revenue, last 12 months $39495 $68909 $725781 $1m $2m $6m $28m
Revenue growth, last 12 months −98.6% −35.9% −2.0% −95.0% −58.3% 133.5% 25.8%
Revenue growth, latest quarter — — — −97.1% — 38.0% 25.1%
Gross margin 100.0% 91.2% 73.5% 10.5% 88.6% 11.1% 40.3%
Operating margin <−999% <−999% −148.1% −429.1% −183.0% −5.1% −154.1%
Operating margin, 3-year average <−999% — — −144.9% — −20.1% −249.9%
Net margin <−999% <−999% −187.7% −437.8% −192.2% −14.5% −99.7%
Cash from operations / revenue <−999% <−999% <−999% −107.9% −40.6% −2.3% −24.5%
Free-cash-flow margin <−999% <−999% <−999% −107.9% −42.6% −2.4% −42.6%
Free-cash-flow margin, 3-year average — — — −35.7% — −9.3% −35.7%
Change in share count −99.6% 0.0% 111.1% 10.4% 65.9% 0.3% 11.5%

Median of all 15 companies we cover in diversified financial services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Insider trading activity

Full insider history and chart

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Sangrix Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Sangrix Inc. in brief

What does Sangrix Inc. do?
Sangrix Inc. is a US-listed company in the diversified financial services industry. Its financial year ends in June.
What is Sangrix Inc.'s stock ticker?
Sangrix Inc. trades under the ticker SGRX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Sangrix Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Sangrix Inc. reported revenue of $39,495, 98.6% lower than a year earlier, according to its SEC filings.
What is Sangrix Inc.'s free cash flow?
Sangrix Inc.'s free-cash-flow margin is -5799.7% of revenue over the trailing twelve months.
What is Sangrix Inc.'s market cap?
On June 30, 2025, Sangrix Inc.'s market capitalisation was about $3.7B and net debt of -$55,639. Market figures come from third-party market data and may be delayed.
Who are Sangrix Inc.'s competitors?
In our Diversified Financial Services peer group, the companies closest to Sangrix Inc. are Sentage Holdings Inc., NFT Ltd, Defi Capital Markets, Inc., Grande Group Ltd and Royalty Management Holding Corp. The side-by-side comparison below sets their revenue, margins and growth against Sangrix Inc.'s.